Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Procter and Gamble delivered a decent top-line growth in the last quarter surpassing Wall Street expectations and continued its strong cash productivity which enables its high dividend payouts.</li><li>Feminine care, fabric care, and Personal health care were up by double digits, whereas personal care, skin and hair care, and oral and home care all grew low-single digit.</li><li>We provide the stock of Procter and Gamble Company with a ‘Hold’ rating with a revision in the target price.</li></ul>

Procter and Gamble delivered a decent top-line growth in the last quarter surpassing Wall Street expectations and continued its strong cash productivity which enables its high dividend payouts.Feminine care, fabric care, and Personal health care were up by double digits, whereas personal care, skin and hair care, and oral and home care all grew low-single digit.We provide the stock of Procter and Gamble Company with a ‘Hold’ rating with a revision in the target price.

Procter & Gamble Company: Financial Forecasts

Equity Capital Markets

Procter & Gamble Co / Equity Capital Markets

<ul><li>Procter & Gamble has commenced 2022 on a positive note and is on track to deliver growth in organic sales and productivity this year.</li><li>As productivity programs ramp up and its price hikes go into effect, the earnings are likely to improve sequentially.</li><li>Foreign exchange, pricing, and productivity savings are the pointers where the company looks to make up for the margin contraction.</li></ul>

Procter & Gamble has commenced 2022 on a positive note and is on track to deliver growth in organic sales and productivity this year.As productivity programs ramp up and its price hikes go into effect, the earnings are likely to improve sequentially.Foreign exchange, pricing, and productivity savings are the pointers where the company looks to make up for the margin contraction.

Procter & Gamble: Market Leadership Story

Credit

<ul><li>P&G is one of the few consumer stables majors that has been able to increase its organic sales despite inflationary headwinds and supply chain issues.</li><li>While most of its peer group struggled to pass on price increases to consumers and grow the top-line the company’s brand power helped it in this process.</li><li>The company’s strong retail relationships are also responsible for the increasing market share for P&G brands.</li></ul>

P&G is one of the few consumer stables majors that has been able to increase its organic sales despite inflationary headwinds and supply chain issues.While most of its peer group struggled to pass on price increases to consumers and grow the top-line the company’s brand power helped it in this process.The company’s strong retail relationships are also responsible for the increasing market share for P&G brands.

Procter & Gamble Co.: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>For many years now, P&G has been considered a solid defensive stock and the Covid-19 pandemic re-emphasized this fact.</li><li>For the year 2021, the company managed to deliver a decent top-line growth and sequential earnings progress despite significant cost headwinds, and continued strong cash productivity.</li><li>They have been able to deliver category growth through constant product innovation and superior execution.</li></ul>

For many years now, P&G has been considered a solid defensive stock and the Covid-19 pandemic re-emphasized this fact.For the year 2021, the company managed to deliver a decent top-line growth and sequential earnings progress despite significant cost headwinds, and continued strong cash productivity.They have been able to deliver category growth through constant product innovation and superior execution.

Procter & Gamble Co.: Financial & Price Forecasts

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop </li>
<li>In Cannabis innovations <a href="https://www.smartkarma.com/entities/philip-morris-international" target="_blank" data-smartkarma-citation="entities:13328:1" rel="noopener">Philip Morris International (PM US)</a>, <a href="https://www.smartkarma.com/entities/canopy-growth-corp" target="_blank" data-smartkarma-citation="entities:25083:1" rel="noopener">Canopy Growth (WEED CN)</a>, <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a><a href="https://www.smartkarma.com/entities/merck-co-inc" target="_blank" data-smartkarma-citation="entities:1130:1" rel="noopener">Merck &amp; Co Inc. (MRK US)</a> and <a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> lead</li>
<li>In overall plant-based extracts innovations <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a>, <a href="https://www.smartkarma.com/entities/eid-parry-india-ltd" target="_blank" data-smartkarma-citation="entities:6925:1" rel="noopener">Eid Parry India (EID IN)</a>, <a href="https://www.smartkarma.com/entities/abbott-laboratories" target="_blank" data-smartkarma-citation="entities:11987:1" rel="noopener">Abbott Laboratories (ABT US), </a>Indena, Mars Incorporated, and Liveleaf are the leaders.</li>
</ul>


Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop 
In Cannabis innovations Philip Morris International (PM US), Canopy Growth (WEED CN), Jazz Pharmaceuticals (JAZZ US)Merck &amp; Co Inc. (MRK US) and Takeda Pharmaceutical (4502 JP) lead
In overall plant-based extracts innovations Jazz Pharmaceuticals (JAZZ US), Eid Parry India (EID IN), Abbott Laboratories (ABT US), Indena, Mars Incorporated, and Liveleaf are the leaders.


Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

United States

The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Procter & Gamble Co (PG US)

Procter & Gamble Company: Financial Forecasts

Procter and Gamble delivered a decent top-line growth in the last quarter surpassing Wall Street expectations and continued its strong cash...

Baptista Research

Procter & Gamble: Market Leadership Story

Procter & Gamble has commenced 2022 on a positive note and is on track to deliver growth in organic sales and productivity this year. As...

Baptista Research

Procter & Gamble Co.: Detailed Credit Analysis & Financial Strength Evaluation Report

P&G is one of the few consumer stables majors that has been able to increase its organic sales despite inflationary headwinds and supply chain...

Baptista Research

Procter & Gamble Co.: Financial & Price Forecasts

For many years now, P&G has been considered a solid defensive stock and the Covid-19 pandemic re-emphasized this fact. For the year 2021, the...

Baptista Research

Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

Herbal medicinal and nutraceutical extracts are seen as instruments to maintain health and treat some conditions. Cannabis, in particular, will see...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)